1EXEL

Exelixis, Inc. develops and commercializes cancer therapies, focusing on small molecules and biotherapeutics. The company engages in drug discovery and development, advancing a pipeline that includes treatments for various cancer types through both internal programs and strategic partnerships. Exelixis operates across multiple modalities and mechanisms of action, including bispecific antibodies and antibody-drug conjugates, and conducts clinical trials aimed at improving patient outcomes in oncology.